Indeed, in the DESTINY-PanTumor02 study, a significant subset of patients with IHC 2+ HER2 expression responded to T-DXd therapy, and studies have demonstrated a significant increase in overall survival and progression-free survival in HER2-low breast cancers.2 The gene discussed is ERBB2; the disease is breast carcinoma.